Risk assessment for adverse drug reactions

Details Risk assessment for adverse drug reactions Risk assessment for adverse drug reactions

2011-06-21

2011-06-21

Kapushoc, Stephen (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200, C435S007100

Reexamination Certificate

active

07964351

ABSTRACT:
The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

REFERENCES:
patent: 5550039 (1996-08-01), Trachtenberg
patent: 6583139 (2003-06-01), Thorsett et al.
Alfirevic A. et al., “HLA-B Locus in Caucasian Patients with Carbamezepine Hypersensitivity,” Pharmacogenomics 7(6):813-818 (Sep. 2006).
Bigby M, Jick S, Jick H, Amdt K. (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.JAMA. 256(24):3358-3363.
Carbamazepine, available online at www.mentalhealth.com/drug/p30-t01.html, pp. 1-17, retrieved on May 5, 2006.
Chan SH and Tan T. “HLA and allopurinol drug eruption”Dermatologica.1989, 179(1):32-3.
Chung, W.H., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486.
Deng et al., “LOD Score Exclusion Analyses for Candidate Genes Using Random Population Samples,” Ann. Hum. Genet. 65 (pt3): 313-329 (May 2001).
Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins.Postgrad Med J.1999, 75(889):680-1.
Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia.Curr Opin Rheumatol.2001, 13(4):285-90.
Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin.Am J Med.1991, 91(6):631-4.
Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity.Biochem Pharmacol.1995, 50(9):1353-9.
Gumperz, J.E., et al. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 181(3):1133-1144.
Gut, J. (2002). Severe adverse drug reactions and theragenomics. Business Briefing Pharmatech. Retrieved from the Internet: URL: http://therastrat.com/downloads/Gut—2002—Servere—Adverse—Drug—Reactions.pdf> retrieved on Oct. 1, 2004.
Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, Kappeler A, von Greyerz S, Braathen LR, Pichler WJ. T cell involvement in cutaneous drug eruptions.Clin Exp Allergy.2001, 31(9):1398-408.
Hildesheim, A., et al. (2002). Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 94(23):1780-1789.
Hoa BK et al., Tissue Antigens, 71:127-134 (2007).
Hung et al., “HLA-B Genotype to Detect Carbamazepine-Induced Stevens-Johnson Syndrome: Implications for Personalizing Medicine,” Personalized Medicine, 2(3): 225-237 (Aug. 2005).
Juppner H., “Functional Properties of the PTH/PTHrP Receptor,” Bone 17 (2 Suppl):39S-42S (Aug. 1995).
Khan MA. Update: the twenty subtypes of HLA-B27.Curr Opin Rheumatol.2000;12(4):235-8.
Lazarou J, Pomeranz BH, Corey PN. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA.279(15):1200-1205.
Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs.Epilepsia.1998, 39 Suppl 7:S8-16.
Lonjou s et al., “A Marker for Stevens-Johnson syndrome . . . :Ethnicity Matters,” Pharmacogenomics J., 1-4 Jan. 17, 2006).
Mallal, S. et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359(9308):727-732.
Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones.Mol Pharmacol.2003, 63(3):732-41.
Nassif, A., et al. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 118(4):728-733.
Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol. 1997, 113(1-3):177-80.
Pirmohamed M , Lin K, Chadwick D, Park BK. TNF∩ promoter region gene polymorphisms in carbamazepine-hypersensitive patients.Neurology.2001, 56(7):890-6.
Pirmohamed, M., and Park, B.K. (2003). Adverse drug reactions: back to the future. Br J Clin Pharmacol. 55(5):486-492.
Romphruk, A., et al. (2003). HLA-B*15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet. 30(2):153-158.
Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs.Tissue Antigens.1986, 28(4):251-4.
Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis.Arch Dermatol.1987, 123(9):1171-3.
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.N Engl J Med.1995, 333(24):1600-7.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs.N Engl J Med.1994, 331(19):1272-85.
Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification.J Invest Dermatol.1994, 102(6):28S-30S.
Sankar, P. , Nature Genetics, vol. 34, p. 119 (2003).
Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment.Arch Ophthalmol.1997, 115(4):550-3.
Svensson CK, Cowen EW , Gaspari, AA. (2000) Cutaneous drug reactions.Pharmacol Rev.53(3):357-379.
Thisted RA “What is P-Value?” available online at http://www.stat.uchicago.edu?˜thisted, pp. 1-6, (1998).
Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.Pharmacogenetics.1995, 5(4):255-8.
Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.Ann Intern Med.1997, 126(8):608-14.

Affiliated with

Also associated with

Rating

Risk assessment for adverse drug reactions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Risk assessment for adverse drug reactions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Risk assessment for adverse drug reactions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2711148